Intra-Cellular Therapies Inc’s filing revealed that its Chairman and CEO Mates Sharon unloaded Company’s shares for reported $2.58 million on Aug 29 ’24. In the deal valued at $72.57 per share,35,604 shares were sold. As a result of this transaction, Mates Sharon now holds 1,070,329 shares worth roughly $78.43 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Mates Sharon sold 34,396 shares, generating $2,505,351 in total proceeds. Upon selling the shares at $72.84, the Chairman and CEO now owns 1,070,329 shares.
Before that, Mates Sharon bought 34,396 shares. Intra-Cellular Therapies Inc shares valued at $2,503,218 were divested by the Officer at a price of $72.78 per share.
Robert W. Baird initiated its Intra-Cellular Therapies Inc [ITCI] rating to an Outperform in a research note published on January 03, 2024; the price target was $83. A number of analysts have revised their coverage, including TD Cowen’s analysts, who began to cover the stock in mid December with a ‘”an Outperform”‘ rating. Morgan Stanley began covering ITCI with “an Overweight” recommendation on April 20, 2023. Goldman revised its rating on August 22, 2022. It rated ITCI as “a Neutral” which previously was an “a Buy”.
Price Performance Review of ITCI
On Friday, Intra-Cellular Therapies Inc [NASDAQ:ITCI] saw its stock jump 1.41% to $73.28. Over the last five days, the stock has lost -1.61%. Intra-Cellular Therapies Inc shares have risen nearly 2.32% since the year began. Nevertheless, the stocks have risen 32.35% over the past one year. While a 52-week high of $84.89 was reached on 04/16/24, a 52-week low of $45.50 was recorded on 02/22/24. SMA at 50 days reached $75.10, while 200 days put it at $69.48.
Levels Of Support And Resistance For ITCI Stock
The 24-hour chart illustrates a support level at 72.50, which if violated will result in even more drops to 71.71. On the upside, there is a resistance level at 73.77. A further resistance level may holdings at 74.26. The Relative Strength Index (RSI) on the 14-day chart is 43.45, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.87, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 79.41%. Stochastics %K at 10.21% indicates the stock is a buying.
How much short interest is there in Intra-Cellular Therapies Inc?
A steep rise in short interest was recorded in Intra-Cellular Therapies Inc stocks on 2024-08-15, dropping by -0.38 million shares to a total of 2.54 million shares. Yahoo Finance data shows the prior-month short interest on 2024-07-15 was 2.92 million shares. There was a decline of -14.94%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on July 07, 2022 when Mizuho began covering the stock and recommended ‘”a Buy”‘ rating along with a $74 price target.
